CyDex, Inc. Licenses Captisol(R) to Critical Therapeutics for Injectable Formulation of Zileuton

Published: Jun 12, 2007

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced the signing of a license and supply agreement granting exclusive worldwide rights to its Captisol® enabling technology to Critical Therapeutics, Inc. (NASDAQ: CRTX) for the development of an injectable formulation of zileuton.

Back to news